SimonTG, MaY, LudvigssonJF, . Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncol. 2018. doi: 10.1001/jamaoncol.2018.4154.
2.
RicciottiE, WangensteenKJ, FitzGeraldGA.Aspirin in Hepatocellular Carcinoma. Cancer Res. 2021;81(14):3751–3761.
3.
LouW, ChenJ, DingB, . Identification of invasion-metastasis-associated microRNAs in hepatocellular carcinoma based on bioinformatic analysis and experimental validation. J Transl Med. 2018;16(1):266.
4.
PordzikJ, PisarzK, De RosaS, . The potential role of platelet-related microRNAs in the development of cardiovascular events in high-risk populations, including diabetic patients: a review. Front Endocrinol (Lausanne). 2018;9:74.
5.
BaoJ, YuY, ChenJ, . MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway. Cell Death Dis. 2018;9(10):1045.
6.
GongC, FangJ, LiG, LiuHH, LiuZS.Effects of microRNA-126 on cell proliferation, apoptosis and tumor angiogenesis via the down-regulating ERK signaling pathway by targeting EGFL7 in hepatocellular carcinoma. Oncotarget. 2017;8(32):52527–52542.
7.
de BoerHC, van SolingenC, PrinsJ, . Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Eur Heart J. 2013;34(44):3451–3457.
